Related Experiment Video
Updated: Aug 6, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53 Orchestrates the Immunogenic-Tolerogenic Pyroptosis Switch in Non-Small Cell Lung Cancer: A Systems Biology
Shantanu Gupta1, Daner A Silveira2, Rodrigo Juliani Siqueira Dalmolin1
1Bioinformatics Multidisciplinary Environment-BioME-Digital Metropole Institute, Federal University of Rio Grande do Norte, Natal 59076550, RN, Brazil.
Abstract:
Resistance to immunogenic cell death drives therapy failure in non-small cell lung cancer (NSCLC). While the tumor suppressor p53 can activate both canonical (NLRP3-caspase-1-GSDMD) and secondary (caspase-9/3-GSDME) pyroptosis, 2 lytic programs with divergent immunogenicity, the systems-level logic coordinating these parallel execution pathways remains unknown, limiting therapeutic exploitation. Here, we deploy, to our knowledge, the first dynamic Boolean network model of p53-regulated pyroptosis in NSCLC to resolve this decision layer. The model suggests that the terminal caspase-gasdermin axis may be structured as a bistable immunogenic switch, governed by interlocked feedback loops: a double-negative motif (caspase-9-caspase-3-GSDMD) that enables mutual exclusivity and a reinforcing loop (GSDME-caspase-9-caspase-3) that commits to secondary pyroptosis. Within the model, this topology positions GSDME not as a passive executioner but as a critical fate-determining node; its loss, frequent in NSCLC, does not abort death signaling but is predicted to re-route p53-engaged caspase-3 activity toward apoptosis, providing a potential explanation for how tumors may evade immunogenic lysis while retaining apoptotic competence. Model predictions are validated against NSCLC cell-line phenotypes and patient transcriptomics, revealing coordinated repression of pyroptosis-execution genes and identifying CASP9/GSDME as adverse prognostic markers. Collectively, our results suggest that p53 functions as a central coordinator of a terminal fate-switch network rather than a simple linear activator and provide a systems-level framework for investigating how execution-layer regulatory circuits influence cell-death outcomes in NSCLC.
Insights
Tumor suppressor p53 regulates cell death pathways in non-small cell lung cancer (NSCLC). A new model reveals p53 controls a switch between pyroptosis and apoptosis, impacting therapy resistance.
Area of Science:
- Cellular biology
- Cancer research
- Systems biology
Background:
- Therapy failure in non-small cell lung cancer (NSCLC) is linked to resistance to immunogenic cell death.
- The tumor suppressor p53 can initiate two distinct pyroptosis pathways: canonical (NLRP3-caspase-1-GSDMD) and secondary (caspase-9/3-GSDME).
- The coordination logic of these parallel p53-regulated cell death pathways is not well understood, hindering therapeutic strategies.
Purpose of the Study:
- To elucidate the systems-level logic governing p53-regulated pyroptosis pathways in NSCLC.
- To model the decision-making process that directs cell death outcomes.
- To identify therapeutic targets for overcoming resistance to immunogenic cell death.
Main Methods:
- Development of the first dynamic Boolean network model for p53-regulated pyroptosis in NSCLC.
- Analysis of feedback loops governing the terminal caspase-gasdermin axis.
- Validation of model predictions using NSCLC cell line phenotypes and patient transcriptomics.
Main Results:
- The p53-regulated terminal caspase-gasdermin axis functions as a bistable immunogenic switch.
- Interlocked feedback loops, including a double-negative motif and a reinforcing loop, control pathway mutual exclusivity and commitment to secondary pyroptosis.
- Loss of GSDME, common in NSCLC, is predicted to redirect p53-activated caspase-3 towards apoptosis, explaining evasion of immunogenic lysis.
- Coordinated repression of pyroptosis-execution genes and identification of CASP9/GSDME as adverse prognostic markers.
Conclusions:
- p53 acts as a central coordinator of a terminal cell fate-switch network, not just a linear activator.
- The study provides a systems-level framework for understanding how cell death execution circuits influence outcomes in NSCLC.
- This framework can guide the development of novel therapeutic strategies targeting cell death pathways in NSCLC.
Related Concept Videos
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
